Mad in America

JANUARY 4, 2025

Of the 4,041 patients who entered the trial, only 108 had remitted and then stayed well and in the study to its one-year end, a documented stay-well rate of 3%. The public now had easy access to source documents that told of how the STAR*D investigators had deviated from the protocol to produce their inflated 67% remission rate.

Pharmaceuticals 145

Pharmaceuticals Neurotransmitters and mental health Sleep and mental health Aging and mental health 145

Mad in America

OCTOBER 30, 2023

Being a former NIMH director, Insel should have told his readers about the poor long-term outcomes of treatment with psychiatric drugs, as documented in expensive and prestigious research funded by the NIMH, e.g. CATIE and STAR*D. Nothing in Insel’s narrative would harm psychiatry’s guild interests or pharmaceutical interests.

Pharmaceuticals 133

Pharmaceuticals Manufacturing Bipolar disorder Self-awareness 133

Mad in America

DECEMBER 20, 2023

For Part 2, we will be covering reader questions on pharmaceutical marketing and issues with psychiatric treatments including psychiatric drugs and electroconvulsive therapy. Moore: The last couple of questions are related to the pharmaceutical industry. Thank you to all of you who took the time and trouble to send in your questions.

Pharmaceuticals 145

Pharmaceuticals Aging and mental health Biopsychosocial model Hospitality 145

Mad in America

OCTOBER 10, 2023

With the explosion of more and more drugs in cabinets across the country, more and more children are dying—but still, pharmaceutical companies push their products, leading to yet more drugs and yet more deaths. Unlike the pharmaceutical industry, in our village community the pain of losing a single child was felt by all.

Manufacturing 142

Manufacturing Pharmaceuticals Aging and mental health Nonprofits 142

Mad in America

OCTOBER 21, 2023

As I documented in CounterPunch earlier this year, it is now mainstream to acknowledge that: (1) psychiatry’s treatment outcomes are “abysmal” and “not getting any better”; (2) the serotonin imbalance theory of depression is untrue; and (3) psychiatry’s diagnostic manual, the DSM , is scientifically invalid.

Technology 144

Technology Genetics and mental health Pharmaceuticals Sleep and mental health 144

Mad in America

DECEMBER 17, 2024

What is at stake here with this discussion is the billion-dollar business that the pharmaceutical companies make with their unproven myth that mental illness results from a chemical imbalance in the brain that can only be corrected by taking antipsychotic drugs. Exile is particularly beneficial for Americans who are recovering from psychosis.

Trauma and the brain 98

Trauma and the brain Aging and mental health Hospitality Bipolar disorder 98